J Korean Med Sci.  2006 Apr;21(2):212-216. 10.3346/jkms.2006.21.2.212.

The Effect of Insulin Resistance on Prognosis of Non-Diabetic Patients Who Underwent Percutaneous Coronary Intervention

• Yun KH
• Jeong MH
• Kim KH
• Hong YJ
• Park HW
• Kim JH
• Ahn YK
• Cho JG
• Park JC
• Kim NH
• Oh SK
• Jeong JW
• Kang JC

• KMID: 1781824
• DOI: http://doi.org/10.3346/jkms.2006.21.2.212

Abstract

Insulin resistance is an important risk factor for coronary artery disease. However, there has been no data regarding its clinical effect on the outcomes of percutaneous coronary intervention (PCI) in non-diabetic patients. We analyzed 98 non-diabetic consecutive patients (59+/-11.5 yr, male:female=63:35) who underwent elective coronary angiography. The patients were divided into two groups: Group I (n=71; the value of HOMA-IR [homeostasis model assessment of insulin resistance] <2.6) and Group II (n=27; the value of HOMA-IR > or = 2.6). In-hospital and 30-day major adverse cardiac events (MACE) were compared between the two groups. The concentrations of fasting insulin and triglyceride were significantly higher in Group II than in Group I. Significant correlations were observed between the value of HOMA-IR and body mass index (r=0.489, p<0.001), levels of total cholesterol (r=0.204, p=0.045), triglyceride (r=0.334, p=0.001) and apolipoprotein B (r=0.212, p=0.038). PCI was performed in 59 patients (60.2%). In-hospital and 30-day MACE were higher in Group II than Group I (2.4% vs. 27.8%, p=0.008; 2.4% vs. 27.8%, p=0.008). Multivariate analysis revealed that the value of HOMA-IR > or = 2.6 was an independent predictor of MACE. Increased HOMA-IR level is an important prognostic indicator in non-diabetic patients underwent PCI.

Keyword

Coronary Disease; Insulin; Prognosis; Angioplasty

MeSH Terms

Prognosis
Models, Biological
Middle Aged
Male
*Insulin Resistance
Humans
Homeostasis
Female
Coronary Stenosis/blood/physiopathology/therapy
Coronary Arteriosclerosis/blood/physiopathology/therapy
*Angioplasty, Transluminal, Percutaneous Coronary/adverse effects
Aged

Reference

1. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, tri-glyceride and insulin concentrations. J Intern Med. 1992. 231:25–30.

2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988. 37:1595–1607.

3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Task-inen MR, Groop L. Cardiovascular morbidity and mortality associ-ated with the metabolic syndrome. Diabetes Care. 2001. 24:683–689.

4. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resis-tance in nondiabetic subjects. Diabetes. 1998. 47:793–800.

5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979. 237:E214–E223.

6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. 28:412–419.

7. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes Care. 1997. 20:1087–1092.

8. Takezako T, Saku K, Zhang B, Shirai K, Arakawa K. Insulin resistance and angiographical characteristics of coronary atherosclerosis. Jpn Circ J. 1999. 63:666–676.

9. Radke PW, Voswinkel M, Reith M, Kaiser A, Haager PK, Hanrath P, Hoffmann R. Relation of fasting insulin plasma levels to restenosis after elective coronary stent implantation in patients without diabetes mellitus. Am J Cardiol. 2004. 93:639–641.

10. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease. Circulation. 1975. 51:5–40.

11. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990. 82:1193–1202.

12. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997. 29:6–12.

13. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996. 93:879–888.

14. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Stroke. 1998. 29:1860–1866.

15. Sung KC, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Rhee EJ, Lee WY, Kim SW, Kim H, Lee KB, Ryu SH. In normoglycemic Koreans, insulin resistance and adipocity are independently correlated with high blood pressure. Circ J. 2004. 68:898–902.

16. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994. 25:66–73.

17. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Insulin sensitivity and atherosclerosis. Circulation. 1996. 93:1809–1817.

18. Haffner SM, D'Agostino R, Mykkanen L, Hales CN, Savage PJ, Bergman RN, O'Leary D, Rewers M, Selby J, Tracy R, Saad MF. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke. 1998. 29:1498–1503.

19. Bavenholm P, Proudler A, Tornvall P, Godsland I, Landou C, de Faire U, Hamsten A. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation. 1995. 92:1422–1429.

20. Mizuno T, Matsui H, Imamura A, Numaguchi Y, Sakai K, Murohara T, Okumura K. Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men. Int J Cardiol. 2004. 97:455–461.

21. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996. 334:952–957.

22. Yanase M, Takatsu F, Tagawa T, Kato T, Arai K, Koyasu M, Horibe H, Nomoto S, Takemoto K, Shimizu S, Watarai M. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J. 2004. 68:47–52.

23. Yarnell JW, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischemic heart disease: are associations explained by triglyceride concentrations: the Caerpholly prospective study. Br Heart J. 1994. 171:293–296.

24. Young MH, Jeng CY, Sheu WH, Shieh SM, Fuh MM, Chen YD, Reaven GM. Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographycally demonstrated coronary artery disease. Am J Cardiol. 1993. 72:458–460.

25. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care. 1996. 19:1–7.

26. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P. Insulin Resistance Atherosclerosis Study Investigators. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004. 27:781–787.

27. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K. Mechanisms of hepatic artery very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem. 2000. 275:8416–8425.

28. Hwang ST, Sung KC, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Rhee EJ, Lee WY, Kim SW, Jeon WK, Lee SJ. Insulin resistance and apolipoprotein B as a metabolic syndrome risk factor in normal glucose tolerance. Korean J Med. 2004. 66:156–166.

29. Corpus RA, O'Neill WW, Dixon SR, Timmis GC, Devlin WH. Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol. 2003. 92:1282–1286.

30. Sekiguchi M, Kurabayashi M, Adachi H, Hoshizaki H, Oshima S, Taniguchi K. Usefulness of insulin resistance measured by homeostasis model assessment in predicting restenosis after coronary stent placement in nondiabetic patients. Am J Cardiol. 2004. 93:920–922.